1. Home
  2. PLSE vs CRVS Comparison

PLSE vs CRVS Comparison

Compare PLSE & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulse Biosciences Inc (DE)

PLSE

Pulse Biosciences Inc (DE)

HOLD

Current Price

$26.30

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$12.14

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLSE
CRVS
Founded
2014
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.2B
IPO Year
2015
2016

Fundamental Metrics

Financial Performance
Metric
PLSE
CRVS
Price
$26.30
$12.14
Analyst Decision
Buy
Strong Buy
Analyst Count
1
6
Target Price
$22.00
$30.17
AVG Volume (30 Days)
336.6K
1.6M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
48.04
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$840.00
N/A
Revenue Next Year
$287.54
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.56
$3.38
52 Week High
$27.98
$26.95

Technical Indicators

Market Signals
Indicator
PLSE
CRVS
Relative Strength Index (RSI) 61.94 36.24
Support Level $17.58 $6.65
Resistance Level $26.30 $19.21
Average True Range (ATR) 1.81 1.04
MACD 0.57 -0.44
Stochastic Oscillator 80.77 13.81

Price Performance

Historical Comparison
PLSE
CRVS

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: